Sector News

Roche boosts digital health stable with MySugr buy

July 3, 2017
Life sciences

Roche has acquired MySugr, a privately held digital diabetes management player, for an undisclosed sum. MySugr’s apps will become a “focal part” of Roche’s strategy for integrated diabetes management.

Founded in 2012, in Vienna, MySugr focuses on app-based care for people with diabetes. Its offerings include the eponymous MySugr app, which automatically syncs data from a range of diabetes devices and provides feedback and motivation to help people manage their disease. It is available in 52 countries and 13 languages.

A user may purchase a “pro” version of the app with additional functions, such as bolus calculation and access to a certified diabetes educator, who gives personalized advice based on the individual’s diabetes data.

The company also offers some web apps and a pair of iOS apps, including a “scanner” app that allows users to transfer data from their blood glucose meter to the mySugr app by taking a picture of the meter’s screen.

“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” said Roche Diabetes Care CEO Roland Diggelmann, in a statement.

MySugr counts Roche Venture Fund and iSeed Ventures among its investors.

The deal comes 4 months after reports emerged that the Swiss pharma was “considering options” for its diabetes care business, including a spinoff or a sale. At the time, Diggelmann put the rumors to rest, saying Roche was on the hunt for deals to prop up diabetes care, the sales of which sank 4% in fiscal 2016 thanks to pricing pressure in the U.S.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.